




Pathophysiology of “Cholinoceptor Supersensitivity” 
in Affective Disorders 
Steven C. Dilsaver 
Phenomenological and physiological variables demonstrate supersensitive changes to 
cholinergic challenge in affective disorder subjects. Theorists generally assume the pri- 
mary defect is the postsynaptic muscarinic receptor. However, in addition to defectiveness 
or up-regulation of this receptor, the appearance of postsynaptic “cholinoceptor super- 
sensitivity” can result from abnormal presynaptic mechanisms, membrane “pathology,” 
derangement of intracystolic mechanisms that amplify effects of receptor-agonist cou- 
pling, or aberrant cholinergic-monoaminergic interaction. This article discusses abnor- 
malities of the postsynaptic receptor, regulation of postsynaptic receptor density, the 
presynaptic muscarinic receptor, and other mechanisms regulating the release of ace- 
tylcholine, membrane dynamics, and “cascade” mechanisms-specijically the phospha- 
tidylinositol (PI) cycle, Caz+ mobilization, and cyclic guanosine monophosphate (GMP) 
generation-as causes of cholinergic system “supersensitivity.” It is suggested that an 
approach to the topic emphasizing site of abnormality will encourage greater clarity of 
thought in the study of the cholinergic component of the pathophysiology of aflective 
illness. 
Introduction 
Basic and clinical investigations suggest that cholinergic systems are involved in the 
pathophysiology of affective disorders, but the nature of cholinergic defects in these 
diseases is not known. Investigators generally imply that muscarinic receptor supersen- 
sitivity is a major factor. This article questions this implication. Evidence for an abnor- 
mality in cholinergic systems provides the context for discussion. 
Drugs activating cholinergic systems produce depressive symptoms (Grob et al. 1947; 
Rowntree et al. 1950; Gershon and Shaw 1961; Bowers et al. 1964; Janowsky et al. 
1972; El-Yousef et al. 1973; Janowsky et al. 1973a,b; Janowsky et al. 1980; Janowsky 
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et al. 1982; Risch et al. 198la,b,c) and neuroendocrine (Carroll et al. 1980; Risch et al. 
198la,b; 1983a,b; Risch 1982; Doerr and Berger 1983) and polysomnographic (Grob et 
al. 1947; Sitaram et al. 1976, 1977, 1980, 1982; Hill et al. 1979, 1980; Gillin et al. 
1980; McCarley 1982) data typical of major depressive disorder (MDD), endogenous 
subtype (Spitzer et al. 1975). Systemically and centrally administered anticholinesterases 
and cholinomimetics cause decreased drive reduction behavior in humans and animals. 
These drugs may be useful in the development of models of hedonic function (Myers 
and Yaksh 1961; Grossman 1962; Stark and Boyd 1963; Carlton 1967; Domino and Olds 
1968; Olds and Domino 1969; Avery 1971; Russell et al. 197la,b; Overstreet et al. 1972). 
Affective disorder patients exhibit supersensitive changes in behavioral (Janowsky et al. 
1980; Risch et al. 198 1 a, b), neuroendocrine (Risch 1982), and polysomnographic (Sitaram 
et al. 1979; Gillin et al. 1980; Sitaram et al. 1982) variables upon cholinergic challenge, 
relative to normal and psychiatrically ill control subjects. These data implicate central 
muscarinic system supersensitivity in some forms of affective illness (Sitaram et al. 1976; 
Hill et al. 1980; Janowsky et al. 1982, 1983; Risch 1982; Risch et al. 1983b). 
Drugs directly blocking postsynaptic central muscarinic receptors have antidepressant 
effects and produce euphoria (Bolin 1960; Tislow 1970; McVicar 1977; Jellinek 1979; 
Kasper et al. 1981; Kaminer et al. 1982; Crawshaw and Mullen 1984; Pullen et al. 1984). 
These agents also produce up-regulation (Takeyasu et al. 1979; Ben-Barak and Dudai 
1980; Rehavi et al. 1980; Wise et al. 1980; Nomura et al. 1982; Ehlert et al. 1983; 
Yamada et al. 1983) and supersensitivity (Domino 1975; Gillin et al. 1979; Sitaram et 
al. 1979; Dilsaver and Greden 1983; Dilsaver et al. 1983) of cholinergic systems. Their 
abrupt withdrawal can precipitate depression (Innes and Nickerson 1975; Dilsaver and 
Greden 1984) and escape of plasma cortisol from suppression by the synthetic cortico- 
steroid dexamethasone (Greden and Dilsaver 1984; Dilsaver and Greden 1985). This is 
consistent with development of cholinergic overdrive consequent to drug withdrawal. 
Pharmaceuticals interfering with the release of acetylcholine by presynaptic mechanisms 
are euphoriants and liable to abuse. Cannabinoids (Layman and Milton 1971; Yoshimura 
et al. 1974; Kumbarachi and Nastuk 1980; Dilsaver et al. 1984), opiates (Jhamandas et 
al. 1970; Domino and Wilson 1973; Jhamandas et al. 1973), barbiturates (Wahlstrom 
and Ekwall 1976; Norberg and Sundwall 1977; Wahlstrom 1978; Wahlstrom and Nordberg 
1979), and ethanol (Tabakoff et al. 1979) all produce this effect. Depressed mood and 
affect, psychic and somatic anxiety, psychomotor retardation, and anorexia and other 
features of meancholia follow discontinuation of these drugs. 
In summary, excessively active central cholinergic networks appear to contribute to 
the genesis of depressive phenomena and inhibition of these systems with the development 
of subjectively desirable states. 
Amitriptyline (Rehavi et al. 1980; Goldman and Erickson 1983) and desipramine 
(Nomura et al. 1982) up-regulate muscarinic receptors in the brain and heart of mice and 
rats, respectively, Desipramine produced a marked increase in the sensitivity of omithine 
carboxylase to muscarinic agonists in rat cardiac muscle and increased quinuclidinyl 
benzilate binding. Tricyclics also cause rapid cycling in bipolar patients (Wehr and 
Goodwin 1979). In contrast, treatments down-regulating or subsensitizing cholinergic 
systems, e.g., seizures (Byrne et al. 1980; Dashieff and McNamara 1980; Dashieff et 
al. 1981, 1982), and lithium (Janowsky et al. 1979; Pestronk et al. 1980; Levy et al. 
1982; Dilsaver 1984) often abort rapid cycling. Dilsaver (1984) recently reviewed the 
effects of tricyclics, lithium, and electroshock (EST) on cholinergic mechanisms and 
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suggested that the hypotheses “up-regulation or supersensitivity of cholinergic systems 
is involved in the induction of tricyclic associated rapid-cycling” and “the probability of 
a bipolar patient who has never exhibited rapid-cycling, developing a rapid-cycling course 
is a function of an enhanced propensity of critical central cholinergic systems to become 
supersensitive in response to endogenous or exogenous (e.g., tricyclic treatment) assaults 
many of us are subjected to without ill effect” are heuristically important. 
Anticholinesterases (Janowsky et al. 1973~; Shopsin et al. 1975) and dietary loading 
with precursors of acetylcholine (Cohen et al. 1980, 1982; Schreier 1982) diminish the 
intensity of manic symptoms. This may be due to cholinergic inhibition of monoaminergic 
activity (Muscholl 1973). In any event, the clinical state labeled “mania” may be char- 
acterized by a hypocholinergic neurobiological state. The converse would be true of 
depressive states. 
Definitions 
The literature pertaining to the topic under discussion often equates “supersensitivity” to 
muscarinic agonists with “supersensitive muscarinic receptor.” This is erroneous. Further, 
this focus on the muscarinic receptor may be a little bit like a spy listening to the sounds 
created by pressing the buttons on a Touchtone telephone without attending to the con- 
versation. The consequence is loss of information. 
Imprecise usage of “up-regulation” and “supersensitivity” and of “down-regulation” 
and “subsensitivity” produces confusion in the literature. The concepts of up-regulation 
and supersensitivity parallel those of down-regulation and subsensitivity. Thus, this dis- 
cussion is restricted to the former pair. “Up-regulation” means there is a significant 
increase in the maximum number of ligand binding sites per unit; typically this is expressed 
in milligrams of protein per milliliter. “Supersensitivity” indicates enhanced receptor- 
mediated responses to direct or indirect agonists. This phenomenon may be receptor 
independent, i.e., supersensitive responses to pharmacological agents do not necessarily 
indicate supersensitivity of the receptor and are not equivalent to up-regulation. Super- 
sensitivity occurs both with and without receptor up-regulation. It can even exist in the 
presence of receptor down-regulation. For instance, EST produces increased sensitivity 
to dopaminergic, serotonergic, and noradrenergic agents in the absence of change in 
receptor binding parameters or even in the presence of receptor down-regulation (Lerer 
and Belmaker 1982). 
Consider this sentence, “Antimuscarinic agents induce up-regulation and supersensi- 
tivity of cholinergic systems” (Dilsaver, in press). “Up-regulation” indicates that the 
density of cholinoceptors is significantly increased due to antimuscarinic treatment. The 
statement also suggests that measurement of behavioral, physiological, or biochemical 
variables during and/or after antimuscarinic treatment, relative to before (baseline), in- 
dicates that a given quantum of cholinergic stimulation now produces an exaggerated 
change in the value of these variables. That is, the dose-response curve is shifted to the 
left. This use of terms promotes accuracy of expression and (as highlighted by the material 
following) focuses attention on the array of factors that may produce an observation 
compatible with postsynaptic “receptor supersensitivity.” It may simultaneously encourage 
intellectual movement away from the postsynaptic receptor. This may not be bad! Finally, 
accurate definitions can promote clarity of thought in considering factors involved in the 
pathophysiology of the affective disorders. 
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Organization of Discussion 
We will consider the theme, “pathophysiology of cholinergic system supersensitivity in 
the affective disorders” according to possible loci of defect. These include the postsynaptic 
receptor, regulation of muscarinic receptor density, the membrane, intracytosolic mech- 
anisms and modes of signal transductance, and abnormalities of choliner- 
gic-monoaminergic interaction. The thrust is conceptual, and the discussion is not in- 
tended to be exhaustive. Methods of studying events at these sites will be highlighted 
where appropriate. 
Abnormalities of the Muscarinic Cholinergic Receptor 
Affective disorder patients could inherit an abnormal muscarinic cholinergic receptor. 
Perhaps this receptor possesses greater affinity for acetylcholine than does the receptor 
of normal subjects. Measurement of the affinity of the human muscarinic receptor for 
acetylcholine in vivo is not possible now. However, imaging strategies, e.g., positron 
emission tomography (PET), may allow estimation of the in vivo affinity of muscarinic 
receptors for an exogenously administered ligand in the near future. 
Frey and associates (Frey 1984; Frey et al. 1985a,b,c) have performed much of the 
preclinical work required before PET studies using a muscarinic receptor ligand can be 
undertaken in humans. This strategy involves the use of a muscarinic receptor radioan- 
tagonist, e.g., [3H]scopolamine, a ligand that binds to the muscarinic receptor with high 
affinity and specificity. The agent is infused into the living animal; thus, the binding to 
the receptor occurs in vivo. The animal is sacrificed shortly after infusion, and brain 
slices are prepared for autoradiographic measurement of binding variables. Unfortunately, 
[3H]scopolamine is not suitable for studies in humans, owing to its long halflife of 12.5 
years and the resulting high dose of radiation subjects would receive per study. A radio- 
isotope with a sufficiently short halflife and that stably binds scopolamine might allow 
in vivo experiments in humans. In the interim, [3H]scopolamine continues to be used in 
preclinical studies. 
It is possible to address the question of whether or not the nicotinic muscarinic receptor 
is a mutant now (Stevens 1985). The amino acid sequence of all four units of the receptor 
is known (Devillers-Thiery et al. 1983; Claudio et al. 1983; Nadi et al. 1984). The same 
principles used in these studies apply to the muscarinic receptor. However, study of the 
muscarinic receptor is hindered by lack of a source of a high concentration of receptors. 
The nicotinic receptor was recently crystallized, and crystallographic studies promise to 
inform us of its dynamic properties. It should also be possible to crystallize the muscarinic 
receptor if it were available in a high enough concentration. The muscarinic receptor can 
be isolated and reconstituted into a membrane now (Shreeve et al. 1984). This may have 
value in studying the functional properties of the receptor, devoid of confounding influ- 
ences. In conclusion, the question of whether or not the muscarinic receptor is abnormal 
in the affective disorders is answerable in principle, but technical problems are currently 
limiting. 
Regulation of Muscarinic Receptor Density 
Affective disorder subjects may have an increased density of postsynaptic central mus- 
carinic receptors. If so, a quantum of acetylcholine might have a greater effect than in 
normal subjects. This abnormality has not, however, been shown to mark affective 
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disorder subjects. Nadi et al. (1984) reported that fibroblasts cultured from affective 
disorder subjects and their ill relatives demonstrated an increased density of muscarinic 
receptor binding sites relative to controls, but this finding was not replicated (Kelsoe et 
al., 1984; Lennox et al. 1985). 
Imaging techniques can in principle address this question. The [3H]scopolamine tech- 
nique developed by Frey et al. (Frey 1984; Frey et al. 1985a,b,c) allows estimation of 
B max. The appropriate ligand would allow estimation of receptor density in humans. In 
conclusion, this is an open question. 
Abnormal Presynaptic Mechanisms 
Presynaptic muscarinic receptors (Sharma and Banerjee 1978; Nordstrom and Bartfai 
1981; Wamsley et al., 1981; Briggs and Cooper 1982; Ehlert et al. 1983; Mantione et 
al. 1983; Reiteri et al. 1983) are localized on both muscarinic (Sharma and Banerjee 
1978; Briggs and Cooper 1982; Reiteri et al. 1983) and adrenergic neurons (Ehlert et al. 
1983). Activation of presynaptic muscarinic receptors on adrenergic neurons can facilitate 
the release of norepinephrine in the periphery, but when situated on muscarinic neurons, 
it decreases the release of acetylcholine (Sorscher and Dilsaver in press). Thus, super- 
sensitivity to cholinergic agonists might result from subsensitivity or down-regulation of 
muscarinic autoreceptors-the organism would tend to a spontaneous “cholinergic over- 
drive” state or have an inability to properly compensate in the face of pharmacologically 
induced cholinergic overdrive. It is possible that in laying emphasis on the postsynaptic 
neuron, we have been focusing attention at the wrong end of the synapse all along. 
A Normal Receptor in an Abnormal Membrane 
Abnormalities of membranes receive little attention in psychiatric circles. This may stem 
from our inability to study membrane pathology and from the lack of training psychiatrists 
have in membrane biology. However, this is a potentially important subject. Possible 
membrane and membrane-related abnormalities include distrubances in the regulation of 
lipid metabolism and fatty acid biosynthesis, abnormalities in the physical properties of 
membranes due to disturbances of membrane composition, peculiarities in ionic or cyclic 
nucleotide concentrations, degree of phosphorylation, as well as other factors. 
Adult-onset diabetes mellitus with obesity is an example of a disorder marked by a 
membrane abnormality. In this disorder, the density of insulin receptors (Cuatrecasas 
1973) on adipocytes and hepatocytes is decreased, though the absolute number of receptors 
per cell may be normal. Binding of the receptor by insulin causes changes in intracellular 
cyclic neucleotide concentration (cyclic GMP, cyclic AMP), and thence, other effects. 
In the liver, for instance, insulin decreases the intrahepatocyte cyclic AMP concentration. 
This deactivates protein kinases, which are enzymes capable of phosphorylating a number 
of other enzymes. The effectiveness of insulin in decreasing cyclic AMP is contingent 
upon the density of bound receptors. Thus, as the area of the cell surface is increased, 
the effectiveness of a given number of molecules is diminished. 
Baron and asssociates (1984) recently discovered that the incorporation of certain fatty 
acids into the cell membrane enhanced the sensitivity of muscarinic receptors. An issue 
is specificity. Fatty acids are detergents and can have nonspecific effects on membranes. 
However, the hypothesis that abnormalities of membrane constitution or function produce 
cholinoceptor supersensitivity in affective disorder patients is quite viable. 
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Abnormal Intracytosolic Mechanisms 
Phosphatidylinositol Cycle and Cyclic GMP Formation 
The binding of an agonist to a receptor triggers a number of events, e.g., opening of ion 
channels, alteration of adenosine triphosphatase (ATPase) activity, mobilization of in- 
tracellular calcium stores, and stimulation of phospholipid turnover, which may increase 
the release of calcium from intracellular sites, have an ionophore effect, or increase the 
activity of cyclases. The issue is “case mechanisms” or “second messengers.” Cell surface 
receptors are coupled to mechanisms translating agonist-receptor coupling into physio- 
logical events. Figure 1 illustrates this. 
Cholinergic systems employ at least two cascade mechanisms-the phosphatidylinos- 
itol cycle and activation of guanylate cyclase. In the periphery, muscarinic receptor- 
mediated activation of the phosphatidylinositol cycle is associated with generation of 
polyphosphatidylinositides and a rise in cytosolic Ca2+ concentration (Downs 1983). The 
polyphosphatidylinositides are a number of phospholipids that include a sugar, inositol. 
The lipid contains fatty acids esterified to a glycerol backbone that also contains arachi- 
donic acid. The resulting compound (phosphatidylinositol) can be phosphorylated at one 
or more hydroxyl sites located on the inositol moiety. Figure 2 illustrates the molecule 
and the points of kinase activity. 
In assays, the level of phosphorylation in response to muscarinic receptor stimulation 
is the variable measured. Phosphatidylinositol replenishes the polyphosphoinositide pool 
via the actions of specific kinases, enzymes that phosphorylate the hydroxyl groups of 
the inositol component of phosphatidylinositol. Constant replenishing of polyphospho- 
inositides allows mobilization of intra- and extracellular calcium ions, presumably via 
the generation of inositol n&phosphate, which is triphosphorylated inositol in isolation. 
Nervous tissue is sensitive to small changes in cytosolic calcium ion concentration 
(Ca’+). These changes can be translated into a variety of responses via, for example. 
alteration of calmodulun, a regulatory protein that binds calcium ions in the micromolar 
concentration range. Calmodulun plays an unusually important role in the regulation of 
neural function. The calcium-activated form of the enzyme activates several enzymes, 
such as a protein kinase, another one of the most important regulatory proteins known. 
Activation of muscarinic receptors can also increase production of cyclic GMP. Snider 
et al. (1984) studied this phenomenon in murine neuroblastoma. The process begins with 
receptor-mediated activation of phospholipase C. The primary substrates for this enzyme 
are the polyphosphoinositides. Inositol phosphates (e.g., inositol n&phosphate) and dia- 
cylglycerol are products of the activity of phospholipase C. Diacylglycerol reacts with 
Figure 1. Agonists sterospecifically bind to receptors, thereby producing secondary effects of 
agonist-receptor coupling, such as increased phosphatidylinositol, cyclic GMP, or cyclic AMP 
turnover, increases in [Ca2+], phosphorylation of regulatory proteins, or activation of other mech- 
anisms. These secondary events can amplify or magnify the effects of receptor activation. Thus. 
activation of the receptor is only one event determining sensitivity to an endogenous or another 
agonist. 






I I I 1 Arachidonic 
Figure 2. Inositolphospholipid consists of a glycerol backbone esterified to a fatty acid, aracidonic 
acid, and inositol, a 6-carbon sugar. The sugar moiety can be phosphorylated, generally at positions 
4 and 5, while in the form of inositols. The resulting compounds are phosphatidylinositol or the 
polyphosphatidylinositols. 
cytosine triphosphate to yield phosphatidic acid. The latter then reacts with inositol to 
reform phosphatidylinositol. Hence, the cyclical process of phosphatidylinositol break- 
down and regeneration, etc. Incidentally, various intermediates in this cycle other than 
inositol trisphosphate may be metabolically active, i.e., directly amplify effects of mus- 
carinic receptor activation. For example, phosphatidic acid may act as a Ca*+ ionophore. 
Turnover of phosphatidylinositol involves a transmembrane event catalyzed by calcium 
bound to intramembrane sites. Initiation of this process, i.e., activation of the phospha- 
tidylinositol cycle, may involve a shift of this bound Ca*+ to other bound sites, e.g., 
phospholipase Al. Thus, [Ca*+J would not change, as it remains compartmentalized. 
Alternatively, Ca* + phospholipid complexes could induce confirmational changes in mem- 
brane proteins, thus activating them. Extracellular calcium is obligatory for muscarinic 
receptor-mediated cyclic GMP formation to occur, but its formation is not contingent on 
an increase in [Ca*+]i. This is consistent with shifts of [Ca*+]i from given sites or locations 
to others. 
In conclusion, muscarinic agonist-muscarinic receptor coupling can produce changes 
in the phospholipid pool consequent to activation of phospholipase C in murine neuro- 
blastoma. This lipase may have a Ca*+ receiving site essential to the neurotransmit- 
ter-receptor-cyclic GMP transduction process and/or it may participate in the production 
of products (lipid metabolites) that activate the cyclase. 
Mutations at any point in the model proposed by Snider et al. (1984) might produce 
a supersensitive response to cholinomimetic challenge or a functionally supersensitive 
cholinergic system at baseline. Such a defect in humans could predispose to affective 
disorders. The correctness of the model is not essential to our purposes. There are many 
conceivable transduction mechanisms, but the same principles apply to all. Currently 
available models foster understanding of the nature of possible mechanisms producing 
the appearance of postsynaptic “cholinoceptor supersensitivity” in the affective disorders. 




Cholinergic agents can indirectly mobilize adrenergic systems. This is manifested by 
increased release, synthesis, and turnover of norepinephrine. Kazic (1973) reported phys- 
ostigmine produced a significant decrease in hypothalamic and brain stem norepinephrine 
levels within 15 min of administration. This could be due to massive release and inadequate 
replacement of this neurotransmitter. An increase in synthesis and turnover of 14C-ty- 
rosine, the precursor of norepinephrine, occurred simultaneously. Seven days of treatment 
with physostigmine increased tyrosine hydroxylase (the enzyme governing the rate-limited 
step in catecholamine synthesis) activity in the hypothalamus and brain stem. Increased 
preganglionic cholinergic activity increases tyrosine hydroxylase synthesis in noradren- 
ergic neurons of peripheral nervous tissue. Cholinergic overdrive. lasting only 60 min, 
caused a measurable increase in the activity of tyrosine hydroxylase 48 hr later (Thoenen 
et al. 1973). Richardson and colleagues ( 1973, 1976) reported that the immediate effect 
of an anticholinesterase is reduced tyrosine hydroxylase activity. This may be due to a 
toxic effect on the enzyme. However, the distal or “rebound” effect is increased tyrosine 
hydroxylase activity. Thus, cholinergic overdrive may contribute to development of a 
monoaminergic overdrive state, should there be compensatory diminution in the activity 
of cholionergic systems concomitant with a cholinergically mediated increase in activity 
of monoaminergic systems (Dilsaver and Greden 1984). 
Acetylcholine can also decrease the release of norepinephrine from adrenergic neurons 
in both brain (Westfall 1973; Hobson 1974; Hobson et al. 1975) and the periphery 
(Muscholl, 1973). Muscarinic agonists reduced the release of norepinephrine, where as 
nicotinic agents increased it in rat hypothalamus (Westfall 1973). The net effect of 
acetylcholine was to decrease the release of norepinephrine unless a calcium-kelating 
agent or muscarinic antagonist was employed. 
Flicker and Geyer (1982b) reported that carbachol produced profound hyperactivity 
lo-40 min after ionophoretic infusion into the dentate gyrus of rats. Strength of response 
and lag time were a function of dose. These findings are not compatible with nonspecific 
effects of the agonist producing behavioral activation. The lag contrasts with immediate 
effects of norepinephrine, dopamine, and dopamine agonists and potentiating agents 
applied to the dentate gyrus or other limbic regions (Beani et al. 1968; Pijninburg et al. 
1973; Anders and Jackson 1975; Costa1 and Naylor 1975; Jackson et al. 1975; Dolphine 
et al. 1977; Jones et al. 1981; Flicker and Geyer 1982a,b,c,d). The latency is consistent 
with the hypothesis that carbachol activates the animal by mobilizing dopaminergic or 
other monoaminergic systems. 
The hypothesis that a hypercholinergic state produces partial denervation of postsyn- 
aptic noradrenergic and dopaminergic neurons is supported by an extensive body of data. 
Chemical or pharmacological denervation is the process whereby exogenously applied 
chemicals or endogenously generated biochemical events result in a functionally signif- 
icant blockade of receptors or a decrease in the release of neurotransmitter. There is 
evidence that this occurs. First, muscarinic agonists modulate the release of monoamines 
and up-regulate and supersensitize monoaminergic systems, and conversely (Beani et al.. 
1968; Anderson et al. 198 1; Ehlert et al. 198 1; Blosser 1983; Dilsaver and Greden 1984). 
Secondly, muscarinic agonists and antagonists decrease and increase the quanta1 release 
of acetylcholine by cholinergic neurons, and down-regulate, up-regulate, subsensitize, 
and supersensitize muscarinic cholinergic systems, respectively (Gazit et al. 1974; Ben- 
Barak et al. 1980; Luqmanc et al. 1979; Overstreet and Yamamura 1979; Russell et al. 
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1979a,b; Schiller 1979; Siman and Klein 1979; Taylor et al. 1979; Naid 1984; Shifrin 
and Klein 1980; Rehavi et al. 1980; Creese and Sibley 1981; Russell et al. 1981; Goldman 
and Erickson 1983). 
Endogenously arising surges in cholinergic activity create the prospect of major com- 
pensatory cholinergic and monoaminergic changes occurring spontaneously in vivo. These 
surges are “endogenous drug effects,” i.e., causally significant biochemical changes in 
the functional state of an organism consequent to factors internal to it. Thus, muscarinic 
cholinergic systems mobilize monoaminergic systems and vice versa. This suggests a 
mechanism accounting for oscillations between hypercholinergic-hypomonoaminergic 
and hypocholinergic-hypermonoaminergic states. These oscillations would correspond to 
states of depression and hypomania or mania. These principles suggest that depression 
of monoaminergic systems by endogenously generated, cholinergic assaults (endogenous 
pharmacological assaults) on these networks increases the probability of a compensatory 
monoaminergic overdrive state developing. Supersensitivity of muscarinic cholinergic 
systems could be due to disturbed cholinergic-monoaminergic interaction (Janowsky et 
al. 1972a,b, 1973b). 
Dilsaver and Greden (1984) and Dilsaver (1984, 1986) have proposed a choliner- 
gic-monoaminergic interaction theory (CMIT) of bipolar disorder. This is a dynamic 
account of the mutual inter- and intraregulation of cholinergic, noradrenergic, dopamin- 
ergic, and serotonergic systems in the pathophysiology of affective disorders. The CMIT 
maintains that virtually everything pertinent to the neurobiology of bipolar disorder is 
carefully regulated. In principle, these variables include receptor density and sensitivity, 
membrane properties, cytosolic Ca ‘+, Mg4+, Na+ and other ionic concentrations, ATPase 
activities, etc. The inclusiveness of the factors controlled stems from the assumption that 
the brain is a unified or purposeful dynamism. 
A distinction of the theory is the positing of homeostatic mechanisms that preserve 
the direction of this dynamism. According to the CMIT, the propensity to oscillate between 
manic and depressed phases is not primarily a function of the severity or magnitude of 
the alternating cholinergic and monoaminergic overdrive states, though this is an important 
variable. The theory attributes primary etiological significance to the defectiveness of 
mechanisms designed to render neural systems resistant to forces potentially inducing 
pathogenic perturbation. The function of these mechanisms is prevention of significant 
deviation once a system is sufficiently perturbed to create a potentially pathogenic neu- 
rophysiological state. The basic etiological principle is “faulty mechanisms allow ‘re- 
storative’ monoaminergic system receptor up-regulation and supersensitivity and mus- 
carinic cholinergic system overdrive states, respectively.” 
Summary 
The concept of a muscarinic cholinergic component to the pathophysiology of the affective 
disorders derives from naturalistic observations and clinical research. This type of study 
can carry us only so far. Basic knowledge regarding the function of central muscarinic 
cholinergic systems allows proposal of hypotheses regarding the cause of this phenom- 
enon. The origin of cholinergic system supersensitivity may indeed be the postsynaptic 
“cholinoceptor.” However, presynaptic mechanisms integral to the regulation of acetyl- 
choline release may also be amiss in affective disorder subjects. Alternatively, both pre- 
and postsynaptic receptors may be normal but embedded in abnormal membranes or 
coupled to aberrant cascade mechanisms. Whatever the actual case, a dissection of cho- 
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linergic systems into components cannot help but encourage careful thinking in this 
exciting and important area of research. The site of “etiology” may be other than we ever 
expected! 
References 
Anders N, Jackson DM (1975): Locomotor activity stimulation in rats produced by dopamine in 
the nucleus accumbens, potentiation by caffeine. J Pharm Pharmacol 27:666-670. 
Andersonn K, Fuxe K, Agnati LF (1981): Effects of single injections of nicotine in the ascending 
dopamine pathways in the rat. Evidence for increases of dopamine turnover in neostriatal and 
mesolimbic dopamine neurons. Acta Physiol Stand 112:345-347. 
Avery DD (1971): Intrahypothalamic adrenergic and cholinergic effects on temperature and ingestive 
behavior in the rat. Neuropharmacology 10:753-763. 
Baron B, Kloog Y, Wise GS ( 1984): Fatty acid incorporation increases the affinity of muscarinic 
cholinergic receptors for agonists. Biochim Biophys Acta 801:342. 
Beani L, Bianchi C (1973): Effect of amantadine on cerebral acetylcholine release and content on 
the guinea pig. Neuropharmacology 12:283-289. 
Beani L, Bianchi C, Santinoceto L, Marchetti P (1968): The cerebral acetylchohne release in 
conscious rabbits with semi-permanently implanted epidural cups. Neuropharmacofogy 7:469-48 I 
Beani L, Beani G. Giacomelli A. Tamberi F (1978): Noradrenaline inhibition of acetylcholine 
release from guinea pig brain. Eur J Pharmacol 48: 179-193. 
Ben-Barak Y, Dudai Y (1980): Scopolamine induces an increase in muscarinic receptor level in 
rat hippocampus. Brain Res 193:309-3 13. 
Berridge MJ, Irvine RF (1984): Inositol trisphosphate, a novel second messenger in cellular signal 
transduction. Nature 3 I2:3 15-32 I 
Blosser JC (1983): B-Adrenergic receptor activation increases acetylcholine receptor number in 
cultured skeletal unusual myotubes. J Neurochem 40:1144-l 149. 
Bolin RR (1960): Psychiatric manifestations of artane toxicity. / Nerv Ment Dis 131:256-259. 
Bowers MB, Goodman E, Sim VM (1964): Some behavioral changes in man following antichol- 
inesterase administration. J Nerv Ment Dis 138:383-389. 
Briggs CA, Cooper JR (1982): Cholinergic modulation of the release of (‘HI-acetylcholine from 
synaptosomes of the mysenteric plexus. / Neurochem 38:501-508. 
Byrne MC, Gottlieb N, McNamara TO (1980): Amygdala kindling induces muscarinic cholinergic 
receptor declines in a highly specific distribution within the limbic system. Symp Neural 69:85-98. 
Carlton PL (1967); Cholinergic mechanisms in the control of behavior by the brain. Psychol Rev 
70: 19-39. 
Carmichael FJ, Israel Y (1975): Effects of ethanol on neurotransmitter release by rat brain cortical 
slices. J Pharmacol 193:824-834. 
Carroll BJ, Greden JF, Haskett R, et al (1980): Neurotransmitter studies of neuroendocrine pathology 
in depression. Acta Psychiatrica Stand 61:183-199, Suppl 280. 
Claudio T, Ballivet M, Patrick J, Heinemann S (1983): Nucleotide and deduced amino acid 
sequences of Torpedo californica acetylcholine receptor A subunit. Proc Nat1 Acad Sci USA 
80:1111-1115. 
Cohen BM, Lipinski JF, Alstesman RI (1982): Lecithin in the treatment of mania. Double-blind, 
placebo-controlled trials. Am J Psychiatry 139:1162-l 164. 
Cohen BM, Miller AZ, Lipinski JF, et al (1980): Lecithin in mania: A preliminary report. Am J 
Psychiatry 137~242-243. 
Coastal B, Naylor RJ (1975): The behavioral effects of dopamine applied intracerebrally to areas 
of the mesolilmbic system. Eur J Pharmacol 32:87-92. 
Crawshaw JA, Mullen PE (1984): A study of Benzhexol abuse. Br J Psychiatry 145:300-303. 
Cholinoceptors in Affective Disorders BIOL PSYCHIATRY 823 
1986;21:813-829 
Creese I, Sibley DR (1981): Receptor adaptations to centrally acting drugs. Annu Rev Pharmacol 
Toxic01 21:317-391. 
Cuatrecasas P (1973): Insulin receptor of liver and fat cell membranes. Fed Proc Am Sot Exp Biol 
32:1838-1846. 
Dashieff RM, McNamara JO (1980): Evidence for an agonist independent down regulation of 
hippocampal muscarinic receptors in kindling. Brain Res 195:345-353. 
Dashieff RM, Byrne MC, Patroni U, McNamara JO (1981): Biochemical evidence of decreased 
cholinergic neuronal communication following amygdala kindled seizures. Brain Res 206:233-238. 
Dashieff RM, Savage DD, McNamara JO (1982): Seizures down-regulate muscarinic cholinergic 
receptors in hippocampal formation. Brain Res 235:327-334. 
Devillers-Thiery A, Giraudat J, Bentaboulet M, Changeux JP (1983): Complete in RNA coding 
sequence of the acetylcholine binding (Y subunit of Torpedo inarmonata acetylcholine receptor: 
A model of the transmembrane organization of the polypeptide chain. Proc Nat1 Acad Sci USA 
80:2067-207 1. 
Dilsaver SC (1984): Lithium’s effects on muscarinic receptor binding parameters: A possible 
relationship to therapeutic efficacy? Biol Psychiatry 19: 1551-1565. 
Dilsaver SC (in press): Pharmacologic induction of cholinergic system up-regulation and super- 
sensitivity in affective disorders research. J Clin Psychopharmucol. 
Dilsaver SC, &eden JF (1983): Antidepressant withdrawal syndromes: Evidence for supersensitivity 
of the cholinergic system as an etiologic factor. J Clin Psychopharmacol 3:330. 
Dilsaver SC, &eden JF (1984): Antidepressant withdrawal phenomena: A review. Biol Psychiatry 
19:237-256. 
Dilsaver SC, Greden JF (1985): The effect of antidepressant withdrawal on the dexamethasone 
suppression test. Psychiatry Res 14:ll l-122. 
Dilsaver SC, Kronfol Z, Greden JF, Sackellares JC (1983): Antidepressant withdrawal syndromes: 
Evidence suporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 3:157-164. 
Dilsaver SC, Leckrone JG, Greden JF (1984): An anticholinesterase-like syndrome precipitated by 
psychotropic withdrawal in a chronic abuser of marijuana. Psychosomatics 8:632-634. 
Doerr P, Berger M (1983): Physostigmine-induced escape from dexamethasone in normal subjects. 
Biol Psychiatry 18:261-268. 
Dolphin AC, Jenner P, Sawaya CB, Marsden CD, Testa B (1977): The effects of bromocriptine 
on locomotor activity and cerebral catecholamines in rodents. J Pharm Pharmacol29:727-734. 
Domino EF (1975): Narcotic agonists and Ach. In: Waser PG (ed), Cholinergic Mechanisms. New 
York: Raven Press, pp 433-453. 
Domino EF, Olds ME (1968): Cholinergic inhibition of self-stimulation behavior. J Pharmacol 
Exp Ther 164:202-211. 
Domino EF, Wilson AE (1973): Effect of narcotic analgesic agonists and antagonists on rat brain 
acetylcholine. J Pharmacol Exp Ther 184: 18-32. 
Downes PC (1983): Inositol phospholipids and neurotransmitter-receptor signalling mechanisms. 
Trend Neurosci 6:313-316. 
Ehlert FJ, Roseke WR, Yamamura HI (1981): Dopaminergic regulation of muscarinic receptor 
binding in the corpus striatum. Proc West Pharmacol Sot 24:93-95. 
Ehlert FJ, et al. (1983): The nature of muscarinic binding. In: Iversen LL, Iversen SD, Snyder SN 
(eds), Handbook of Psychopharmacology, vol 17. New York: Plenum. 
El-Yousef MK, Janowsky DS, Davis JM, et al (1973): Induction of severe depression by physo- 
stigmine in marijuana intoxicated individuals. Br J Addict 68:321-325. 
Fibiger HC, Lynch GS, Cooper HP (1971): A biphasic action of central cholinergic stimulation 
on behavioral arousal in the rat. Psychopharmacology 20:36&382. 
Fibiger HC, Lytle LD, Campbell BA (1970): Cholinergic modulation of adrenergic arousal in the 
developing cat. J Camp Physiol Psycho1 3:384-389. 
824 BIOL PSYCHIATRY 
1986;21:813-829 
S.C. Dilsaver 
Fisher SK, Van Rooijen LAA, Agranoff BW (1984): Renewed interest in the polyphosphainositides. 
Trend Neurosci 753-56. 
Fisher SK, Agranoff BW (1985): The biochemical basis and functional significance of enhanced 
phosphatidate and phosphainositide turnover. In Eichberg J (ed), Phospholipids in Nervous 
Tissues. New York: John Wiley and Sons. 
Fisher SK, Klinger PD, Agranoff BW (1982): Muscarinic agonist binding and phospholipid turnover 
in brain. .I Biol Chem 258:7358-7363. 
Flicker C, Geyer MA (1982a): Behavior during hippocampal microinfusions. 1. Norepinephrine 
and diversive explorations. Brain Res Rev 4:79-103. 
Flicker C, Geyer MA (1982b): Behavior during hippocampal microinfusion. II. Muscarinic loco- 
motor activiation. Brain Res Rev 4:105-127. 
Flicker C, Geyer MA (1982~): Behavior during hippocampal microinfusions. III. Lidocaine versus 
picrotoxin. Brain Res Rev 4: 129-I 36. 
Flicker C, Geyer MA (1982d): Behavior during hippocampal microinfusions. IV. Transmitter 
interactions. Brain Res Rev 4: 137-147. 
Frey K (1984): The in vivo determination of ligand binding within the central nervous system. 
University of Michigan, Ann Arbor: University Microfilms. 
Frey KA, Ehrenkaufer RLL, Agranoff RW (1985a): Quantitative in vivo receptor binding. II. 
Autoradiographic imaging of muscarinic cholinergic receptors. Neuroscience (in press). 
Frey KA, Hichwa RD, Ehrenkaufer RLL, Agranoff RW (1985b): Quantitative in vivo receptor 
binding. III. Tracer kinetic modeling of muscarinic cholinergic receptor binding. Neuroscience 
(submitted). 
Frey KA, Ehrenkaufer S, Beaucage S, Agranoff BW (1985~): Quantitative in vivo receptor binding. 
I. Theory and application of the muscarinic cholinergic receptor. J Neurosci 5:421-428. 
Gazit, H, Silaman I, Dudai Y (1974): Administration of an organophosphate causes a decrease in 
muscarinic receptor levels in rat brain. Brain Res 174:354-356. 
Gershon S, Shaw FH (1961): Psychiatric sequelae of chronic exposure to organophosphorus in- 
secticides. Lancer i:1371-1374. 
Gillin JC, Sitaram N, Duncan WC (1979): Muscarinic supersensitivity: A possible model for the 
sleep disturbance of primary depression? Psychiatry Res 1: 17-22. 
Gillin JC, Sitaram N, Duncan WC, Gershon ES, Numberger J, Post RM, Murphy DL, Wehr T, 
Goodwin FK, Birney WL (1980): Sleep disturbance in depression: Diagnostic potential and 
pathophysiology. Psychopharmacol Bull 16:40-42. 
Goldman ME, Erickson CK (1983): Effects of acute and chronic administration of antidepressant 
drugs in the central cholinergic nervous system: Comparison with anticholinergic drugs. Neu- 
ropharmacology 22: 1285-l 222. 
Greden JF, Dilsaver SC (1984): Errors in administration of the dexamethasone suppression test. 
Arch Gen Psychiatry 411725-766. 
Grob D, Harvey AM, Langworthy OR, Lilenthal JL (1947): The administration of diisopropyl- 
fluorophosphonate (DFP) to man. Johns Hopkins Hosp Bull 81:257-2&j. 
Grossman SP (1962): Direct adrenergic and cholinergic stimulation of hypothalamic mechanisms. 
Am J Physiol 202:872-882. 
Hill SY, Reyes RB, Kupfer DJ (1979): Physostigmine induction of REM sleep in imipramine 
treated rats. Commun Psychopharmacol 31261-266. 
Hill SY, Reyes RB, Kupfer DJ (1980): Imipramine and REM sleep: Cholinergic mediation in 
animals. Psychopharmacology 69:5-9. 
Hobson JA (1974): The cellular basis of sleep cycle control. In Weitzman ED (ed) Advances in 
Sleep Research. New York: Spectrum, pp 217-250. 
Hobson JA, McCarley RW, Wyzinski PW (1975): Sleep cycle oscillation: Reciprocal discharge 
by two brain stem neuronal groups. Science 189:55-58. 
Cholinoceptors in Affective Disorders BIOL PSYCHIATRY 825 
1986;21:813-829 
Innes IR, Nickerson M (1975): Atropine, scopolamine and related antimuscarinic drugs. In Goodman 
LS, Gilman A (eds): The Pharmacological Basis of Therapeutics (ed 5). New York: Macmillan, 
p 520. 
Jackson DM, Anden NE, Dahlstrom A (1975): A functional effect of dopamine in the nucleus 
accumbens and in some other dopamine-rich parts of the rat brain. Psychaphannucology 45: 139-149. 
Janowsky DS, El-Yousef MK, Davis JM, et al (1972a): A cholinergic adrenergic hypothesis of 
mania and depression. Luncet ii:632435. 
Janowsky DS, El-Yousef MK, Davis JM, et al (1972b): Cholinergic antagonism of methylphenidate- 
induced sterotyped behavior. Psychopharmacology 27:295-303. 
Janowsky DS, El-Yousef MK, Davis JM, et al (1973a): Acetylcholine and depression. Psychosom 
Med 35:568. 
Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1973b): Antagonistic effects of physostigmine 
and methylphenidate in man. Am J Psychiatry 130:1370-1376. 
Janowsky DS, El-Yousef MK, Davis JM, et al (1973~): Parasympathetic suppression of manic 
symptoms by physostigmine. Arch Gen Psychiatry 281542-547. 
Janowsky DS, Abrams AA, Groom GP, Cloptin P (1979): Lithium antagonizes cholinergic effects 
in rodents. Psychopharmacology 63: 147-150. 
Janowsky DS, Risch SC, Parker D, et al (1980): Increased vulnerability to cholinergic stimulation 
in affect disorder patients. Psychophurmucol Bull 16:29-31. 
Janowsky DS, Risch SC, Judd LL, Parker DC, Kalin NH, Huey LY (1982a): Behavioral effects 
of physostigmine in affective disorder patients. In Clayton PJ, Bennett JR (eds), Treatment of 
Depression. New York: Raven. 
Janowsky DS, Risch SC, Judd LL, Parker D, et al (1982b): Behavioral-neuroendocrine effects of 
physostigmine. Collegium Intemationale Neuropsychopharmacologicum, 13th C.I.N.P. Con- 
gress, Jerusalem, Israel, p 349. 
Janowsky DS, Risch SC, Huey L, Judd LL, Rausch JL (1983): Hypothalamic-pituitary-adrenal 
regulation, neurotransmitters and affective illness. Peptides 4:775-784. 
Jellinek, T (1979): Mood elevating effects of trihexyphenidyl and biperidin in individuals taking 
antipsychotic medication. Dis Nerv Syst 38:353-355. 
Jhamandas K, Tinsley C, Phillis JW (1970): Effects of morphine and its antagonists on release of 
cerebral cortical acetylcholine. Nature 228: 176-177. 
Jhamandas K, Sutar M, Bell S (1973): Modification of precipitated morphine withdrawal syndrome 
by drugs affecting cholinergic mechanisms. Eur J Phurmacol24:296-305. 
Jones DL, Berg SI, Dill D, Dill R (1981): Biphasic locomotor response to intra-accumbens dopamine 
in a nonhuman primate. Phurmucol Biochem Behuv 15:243-246. 
Kaminer Y, Munitz H, Wijsenbelc H (1982): Trihexyphenidyl (artane) abuse: euphoriant and 
anxiolytic. Br J Psychiatry 140:473-474. 
Kasper, S., Moises HW, Beckmkan H (198 1): The anticholinergic biperidin in depressive disorders. 
Pharmacopsychiutry 14:195-198. 
Kazic I (1973): Nompinephrine synthesis and turnover in the brain: Acceleration by physostigmine. 
In Usdin E, Snyder SH (eds), Frontiers in Cutecholumine Research. Oxford: Pergamon Press, 
pp 897-899. 
Kelsoe JR, Gillin JE, Janowsky DJ, Brown JH, Risch SC, Lunkin B (1984): Failure to confirm 
muscarinic receptors on skin fibroblasts. N Engl J Med 312:861-862. 
Kumbarachi MN, Nastuk WL: (1980): Effect of A9-tetrahydrocannabinol on excitable membranes 
and neuromuscular transmission. Molec Phurmucol 17:344-345. 
Layman JM, Milton AS (1971): Some actions of A’-tetrahydrocannabinol and cannabinoids at 
cholinergic functions. Br J Phurmacol41:379P-380P. 
Lennox RH, Hitzemann RJ, Richelson E, Kelsoe JR (1985): Failure to confirm muscarinic receptors 
on skin fibroblasts. N Engl J Med 312:861. 
826 BIOL PSYCHIATRY 
1986:21:813-X29 
S.C. Dilsaver 
Lerer B, Belmaker RH (1982): Receptors and the mechanism of action of ECT. Biol Psychiatry 
17:497-5 11. 
Levy A, Zohar J, Belmaker RH (1982): The effect of chronic lithium treatment in rat brain 
muscarinic receptor regulation. Neuropharmacology 2 1: 1199-l 20 1. 
Luqmanc YA, et al (1979): Depolarization-induced changes in muscarinic cholinergic receptors in 
synaptosomes. Nature (Lond) 27 1:48 1483. 
Manitone CR, Sigmond MJ, Fisher A, Hanin I (1983): Selective presynaptic cholinergic neuro- 
toxicity following intrahippocampal AF64A injection in rats. Neurochemistry 4 1:25 l-255 
McCarley RW (1982): REM sleep and depression-Common neurobiological control mechanisms. 
Am J Psychiatry 139:565-570. 
McVicar K (1977): Abuse of antiparkinson drug by psychiatric patients. Am J Psychiarp 138:809-811. 
Muscholl E (1973): Regulation of catecholamine release. The muscarinic inhibitory mechanism. 
In Usdin G and Snyder SH (eds), Frontiers in Catecholamine Research. New York: Pergamon 
Press, pp 537-549. 
Myers RD, Yaksh TL ( 196 1): Feeding and temperature responses in unrestrained rat after injections 
of cholinergic and aminergic substances into the cerebral ventricles. Physiol Behav 3:917-928. 
Nadi RS, Numberger JI, Gershon ES (1984): Muscarinic cholinergic receptors on skin tibroblasts 
in familial affective disorder. N Engl J Med 311:225-230. 
Noda M, Takahashi H, Tanabe T, Toyosato M. Kikyotani S, Furutani Y. Hirose T, Takashima 
H, Inayama S, Miyata T, Numa S (1983): Structure homology of Torpedo californica acetyl- 
choline receptor subunits. Nature 302:528-532. 
Nomura Y, Kajiyama H, Okai K (1982): Influence of repeated administration of dysmethylimi- 
pramine on B-adrenergic and muscarinic cholinergic receptors and Ca4’ binding to sarcoplasmic 
retriculum in the rat heart. J Pharmacol Exp Ther 223:834-840. 
Nordberg A, Sundwall A (1977): The effect of sodium pentobarbital on the apparent turnover of 
acetylcholine in different brain regions. Acta Physiol Sand 99:33&344. 
Nordberg A, Wahlstrom G (1981): Changes in cholinergic function in the rat brain late in the 
abstinence after chronic barbital treatment. Drug Alcohol Depend 7:5 I-6 1. 
Nordstrom 0, Bartfai T (198 1): 8-BR-cyclic GMP mimics activation of muscarinic autoreceptors 
and inhibits acetylcholine release from rat hippocampal slices. Bruin Res 2 13:467-47 1, 
Olds M, Domino EF (1969): Comparison of muscarinic and nicotinic cholinergic agonists on self- 
stimulation behavior. J Pharmacol Exp Ther 166: 189-204. 
Overstreet DH, Yamamura HI (1979): Receptor alterations and drug tolerance. L$e Sci 25: 1865-1878. 
Overstreet DH, Hadick DG, Russell RW (1972): Effects of amphetamine and pilocarpine on eating 
behavior in rats with chronically low acetylcholinesterase levels. Behav Biol 7:217-226. 
Pestronk A, Drachman DB (1980): Lithium reduces the number of acetylcholine receptors in skeletal 
muscle. Science 2 10:342. 
Pestronk A, Drachman DB, Stanley EF, et al (1980): Cholinergic transmission regulates extra- 
junctional acetylcholine receptors. Exp Neurol 70:690-696. 
Pijninburg AJ. Van Russum J, Rossum JM (1973): Stimulation of locomotor activity following 
injection of dopamine into the nucleus accumbens. J Pharm Pharmacol25: 100-105. 
Pullen GP, Best NR, Maguire J (1984): Anticholinergic drug abuse. A common problem? Br Med 
J 289:612-613. 
Rabin RA, Wolfe BB, Dibner MD, et al (1980): Effects of ethanol administration and withdrawal 
on neurotransmitter receptor systems in 157 mice. J Pharmacol Exp Ther 213:491496. 
R&vi M. Ramot 0. Yavetz B, et al (1980): Amitriptyline: Long-term treatment elevates o- 
adrcnergic and muscarinic receptor binding in mouse brain. Brain Res 194:443453. 
Reiteri M, Marchi M, Maura G (1983): Chronic drug treatments induce changes in the sensitivity 
of presynaptic autoreceptors but not of presynaptic heteroceptors. Eur J Pharmacol9 I : 14 l- 143. 
Cholinoceptors in Affective Disorders BIOL PSYCHIATRY 827 
1986;21:813-829 
Richardson JS. (1973): Cholinergic regulation of tyrosine hydroxylase. In Usdin E, Snyder SH 
(eds) Frontiers in Cutecholamine Research. New York: Pergamon Press. 
Richardson JS (1979): Cholinergic regulation of adrenergic activity in the brain. Proceedings, 
Canadian Federation of Biological Sciences, McMaster University, June 25-28, 1974. 
Richardson JS, Lamprecht F, Kazic T, Kupin IS (1976): Reduction in brain tyrosine hydroxylase 
activity following acetylcholinesterase blockade in rats. Can .I Physiol Pharmacol54:774-718. 
Risch SC (1982): B-Endorphin hypersecretion in depression: Possible cholinergic mechanisms. Biol 
Psychiatry 17:1071-1079. 
Risch SC, Cohen PM, Janowsky DS, et al (1981a): Physostigmine induction of depressive symp- 
tomatology in normal human subjects. J Psychiatr Res 4:89-94. 
Risch SC, Cohne RM, Janowsky DS, Kalin NH, Murphy DL (1981b): Plasma B-endorphin and 
cortisol elevations accompany the mood and behavioral effects of physostigmine in man. Science 
209:1545-1546. 
Risch SC, Kalin NH, Janowsky DS (1981~): Cholinergic challenges in affective illness: Behavioral 
and neuroendocrine correlates. J Clin Psychopharmacol 1: 186-192. 
Risch SC, Janowsky DS, Gillin J (1983a): Muscarinic supersensitivity of anterior pituitary ACTH 
and B-endorphin release in major depressive illness. Peptides 4:789-792. 
Risch SC, Kalin NH, Janowsky DS, et al (1983b): Co-release of ACTH and B-endorphin immu- 
noreceptivity in human subjects in response to central cholinergic stimulation. Science 222:75. 
Rowntree DW, Neven S, Wilson A (1950): The effects of diisopropylfluorophosphonate in schizo- 
phrenia and manic depressive psychosis. J Neurosurg Psychiatry 13:47-62. 
Russell RW, Vasquez BJ, Overstreet DH, Dalglish FW (1971a): Effects of cholinolytic agents on 
behavior following development of tolerance to low cholinesterase activity. Psychopharmacology 
20:32-41. 
Russell RW, Vasquez BJ, Overstreet DH, Dalglish FW (1971b): Consummatory behavior during 
tolerance to and withdrawal from chronic depression of cholinesterase activity. Physiol Behav 
7~523-528. 
Russell RW, Carson VG, Jope R, et al (1979a): Development of behavioral tolerance: A search 
for subcellular mechanisms. Psychopharmacology 66:155-158. 
Russell RW, Overstreet DH, Cotman CW, et al (1979b): Experimental tests of hypotheses about 
neurochemical mechanisms underlying tolerance to the anticholinesterase diisopropylfluoro- 
phosphonate. J Pharmacol Exp Ther 192:73-85. 
Russell RW, Carson VG, Booth RA, Tenden DJ (1981): Mechanisms of tolerance to the anti- 
cholinesterase DFP: Acetylcholine levels and dynamics in the rat brain. Neurophurmacology 
20:1197-1220. 
Schiller GD (1979): Reduced binding of [3H]quinuclidinyl benzilate associated with low acetyl- 
cholinesterase activity. Life Sci 24:1159-l 164. 
Schreier HA (1982): Mania responsive to lecithin in a 13-year-old girl. Am J Psychiatry 139: 108-l 10. 
Sharma VK, Banerjee SP (1978): Presynaptic muscarinic cholinergic receptors. Nature 276278. 
Shifrin GS, Klein WL (1980): Regulation of muscarinic acetylcholine receptor concentration in 
cloned neuroblastoma cells. J Neurochem 34:993-999. 
Shopsin B, Janowsky DS, Davis JM, et al (1975): Rebound phenomena in mania patients following 
physostigmine . Neuropsychobiology 1: 180-l 83. 
Shreeve SM, Roeske WR, Venter JC (1984). Partial functional reconstitution of the cardiac mus- 
carinic cholinergic receptor. J Biochem 259: 12,398-12,402. 
Siman RG, Klein WL (1979): Cholinergic activity regulates muscarinic receptors in central nervous 
system cultures. Proc Nat1 Acad Sci USA 76:4141-4145. 
Sitaram N, Wyatt RJ, Dawson SJ, Gillin CJ (1976): REM sleep induction by physostigmine infusion 
during sleep. Science 191:1281-1283. 
828 BIOL PSYCHIATRY 
1986;21:813-829 
S.C. Dilsaver 
Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC (1977): The time dependent induction of REM 
sleep and arousal by physostigmine infusion during normal humnan sleep. Bruin Res 122562-567. 
Sitaram N, Moore AM, Gillin JC (1979): Scopolamine-induced muscarinic supersensitivity in 
normal man: Changes in sleep. Psychiurry Res 1:9-16. 
Sitaram N, Numberger J, Gershon E, et al (1980): Faster cholinergic REM sleep induction in 
euthymic patients with primary affective illness. Science 208200-202. 
Sitaram N, Numberger J, Gershon E, Gillin JC (1982): Cholinergic regulation of mood and REM 
sleep: Potential model and marker of vulnerability to affective disorders. Am J Psychiatry 
139571-576. 
Smith TL (1983): Influence of chronic ethanol consumption on muscarinic receptors and their 
linkage to phospholipid metabolism in nouse synaptosomes. Neuropharmacology 22:661X167. 
Snider RM, McKinney M, Forray C, Richelson E (1984): Neurotransmitter receptors mediate cyclic 
GMP formation by involvement of arachidonic acid and lipoxygenase. Proc Nat1 Acad Sci USA 
81:3905-3909. 
Sokolovsky M, Gurwitz D, Galron R (1980): Muscarinic receptor binding in mouse brain: regulation 
by guanine nucleotides. Biochem Biophys Res Commun 94~487-492. 
Sorscher SM, Dilsaver SC (in press): Antidepressant induced sexual dysfunction in males: Due to 
cholinergic blockade? J Clin Psychopharmacol. 
Spitzer RL, Endicott J, Robbins E (1975): Research Diagnostic Criteria (ed 2). New York: New 
York State Department of Mental Hygiene, New York Psychiatric Institute, Biometrics Research. 
Stark P, Boyd E (1963): Effects of cholinergic drugs on hypothalamic self-stimulation response 
rates of drugs. Am J Physiol 205:745-748. 
Stevens CF (1985): AchR structure-a new twist to the story. Trend Neurosci 8:1-2. 
Tabakoff B, Muroz-Marcus M, Fields JZ (1979): Chronic ethanol feeding produces an increase in 
muscarinic cholinergic receptors in mouse brain. Life Sci 25: 2173-2180. 
Takeyasu K. Uchida S, Noguchi Y (1979): Changes in brain umscarinic acetylcholine receptors 
and behavioral responses to atropine and morphine in chronic atropine treated rats. Life Sci 
25:585-592. 
Taylor JE, El-Fakanay E, Richelson E (1979): Long-term regulation of muscarinic acetylchohne 
receptors on cultured nerve cells. Life Sci 25:2181-3187. 
Thoenen H, Otten 0, Oesch R (1973): Trans-synaptic regulation of tyrosine hydroxylase. In Usdin 
E, Snyder SH (eds), Frontiers in Catecholamine Research. New York: Pergamon Press, pp 
181-193. 
Tislow RF (1970): Long-term therapy with anticholinergic drugs in psychiatric patients. Phar- 
macology 29:486Ab. 
Wahlstrom G (1978): Estimation of brain sensitivity to the convulsive effects of choline and changes 
induced by chronic barbital treatments in the rat. Eur J Pharmacal 5 I:2 19-227. 
Wahlstrom G, Ekwall T (1976): Tolerance to hexobarbital and supersensitivity to pilocarpine after 
chronic barbital treatments in the rat. Eur J Pharmacol 38: 123-129. 
Wahlstrom G, Nordberg (1979): Sensitivity to an active synaptosomal uptake of choline in the 
abstinence after chronic barbital treatments. Acra Physial Scand Suppl 473:65-203. 
Wamsley JK, Zarbin MA, Kuhar JM (1981): Muscarinic cholinergic receptors flow in the sciatic 
nerve. Brain Res 217:155-161. 
Wehr TA, Goodwin FK (1979): Rapid cycling manic-depressives induced by tricyclic antidepres- 
sants. Arch Gen Psychiatry 15:149-154. 
Westfall TC (1973): Effect of acetylcholine on the release of [H3] norepinephrine by nicotine and 
potassium chloride from rat brain slices. In Usdin E, Snyder SH (eds), Frontiers in Catechol- 
amine Research. New York: Pergamon Press, pp 617-618. 
Wise BC, Shoji, Koo JF (1980): Decrease or increase in cardiac muscarinic cholinergic receptor 
number in rats treated with methacholine or atropine. Biachem Biophys Res Comm 92: I 132-l 142. 
Cholinoceptors in Affective Disorders BIOL PSYCHIATRY 
1986;21:813-829 
829 
Yamada S, Iogai M, Okudaira H, Hayashi E (1983): Regional adaptation of muscarinic receptors 
and choline uptake in brain following repeated administration of diisopropylfluorophosphonate 
and atmpine. Brain Res 1983;268:315-320. 
Yoshimura H, Fujiwara M, Ueki S (1974): Biochemical correlates in moue-Kipling behavior of 
the rat: Brain acetyicholine and acetylcholinesterase after ad~nis~tion of A9-te~ahyd~an- 
nabinol. Brain Res 8 1:567-570. 
